

August 24, 2010



## **OXIS International, Inc. Announces the Introduction of Breakthrough New Ergothioneine-Based Supplements for Joint Health and Healthy Aging**

BEVERLY HILLS, Calif., Aug. 24 /PRNewswire/ -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) is proud to announce that it will introduce the benefits of Ergothioneine to the consumer market in September 2010 via breakthrough products for joint health and healthy aging. The first products, ErgoFlex® and ErgoPlex®, will initially be marketed via a direct mail offering being developed in partnership with Creative Direct Marketing Group, the leading service provider in the direct mail sector of the direct to consumer channel.

"These exciting new formulas provide a previously unavailable suite of benefits to the growing number of baby boomers and younger active lifestyle consumers seeking better solutions to combat the effects of aging in general and more specifically, joint pain," stated Bernie Landes, President of Oxis. "These products provide a unique blend of Ergothioneine and complementary and synergistic ingredients that treat aging and joint health as multidimensional complexes," he added. "By taking advantage of the unique functional benefits of Ergothioneine alone and as a co-factor with other key nutraceutical compounds, we believe that Oxis will be able to provide highly beneficial, proprietary solutions unavailable from any other products in the market today," Landes concluded.

With the introduction of these products, Oxis will stand alone as a supplier of Ergothioneine based products to the global market. These initial products are part of a broad strategy to develop the growing market opportunities for proprietary new approaches to dietary supplement, functional food and beverage and personal care products.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to provide superior solutions to health challenges associated with oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO

(myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.

#### Forward-Looking Statement

This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.

SOURCE OXIS International, Inc.